Protocol Ledger

NCT03435796 · Phase II/III · RECRUITING

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Interventional Phase II/III clinical trial protocol NCT03435796 sponsored by Bristol Myers Squibb in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-07-19 Enrollment: 1,541 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03435796
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,541 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03435796
Protocol FieldVerified Registry Value
NCT IdentifierNCT03435796
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,541 participants (ESTIMATED)
Registered Start Date2018-07-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI